No significant benefit was found for oral antivirals prescribed beyond 5 days of confirmed infection.
New data show Paxlovid outperforms molnupiravir against severe COVID-19 outcomes
More from COVID-19More posts in COVID-19 »
- Data suggest SARS-CoV-2 could jump from raccoon dogs to people, but species barrier may interfere
- Quick takes: Moderna’s RSV vaccine, flu-COVID combo vaccines, new polio cases
- Study: US children at times received ineffective COVID-19 treatments
- NIH announces long-COVID trials to examine treatments for sleep, exercise disruptions